Globus Medical stock is down today on an unexpectedly soft Q1 amid an earlier-than-planned integration with recently acquired ...

On the heels of a first quarter sales dip, leaders remain confident in Globus Medical’s full-year success, according to a May 8 earnings call. 1. Globus Medical’s Excelsius robotic technologies are ...

Joining today's call from Globus Medical will be Dan Scavilla, President and CEO, and Keith Pfeil, Chief Operating Officer and Chief Financial Officer. This review is being made available via webcast, ...

Piper Sandler analyst Matt O’Brien lowered the firm’s price target on Globus Medical (GMED) to $80 from $100 and keeps an Overweight rating on the ...

Globus Medical now expects adjusted per-share earnings of $3 to $3.30 for the year, down from a prior outlook of $3.10 to $3.40. It backed its full-year sales forecast of $2.8 billion to $2.9 billion.

Medical device company Globus Medical (NYSE:GMED) in Q1 CY2025, with sales falling 1.4% year on year to $598.1 million. On ...

Detailed price information for Globus Medical Inc (GMED-N) from The Globe and Mail including charting and trades.

Globus Medical expects full-year earnings in the range of $3 to $3.30 per share, with revenue in the range of $2.8 billion to $2.9 billion. This story was generated by Automated Insights ( ...

If you’ve ever gone to the doctor with a concern and felt like they were downplaying your symptoms—or straight up not ...

Globus Medical (GMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

As you can see from the chart above the percentage of shares that are sold short for Globus Medical has grown since its last report. This does not mean that the stock is going to fall in the near ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Jair Bolsonaro’s medical condition has worsened, nearly two weeks after the former president of Brazil ...